Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04060407 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)(CINDI) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma(PANC-001) | withdrawn | Phase 1 | 0 | Roger Williams Medical CenterOTHER |
| 1 |
| Jun 1, 2021 |
| clinicaltrials |
| NCT03068832 | Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | May 25, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03586024 | Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT03706274 | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors | withdrawn | Phase 1 | 0 | CytomX TherapeuticsINDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03605589 | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | withdrawn | Phase 1 | 0 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03920631 | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas(MicroBLITZ) | withdrawn | Phase 1 | 0 | Ahmed Galal, MDOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03380689 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer(SIRB2) | withdrawn | Phase 1 | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 8, 2021 | clinicaltrials |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 4, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT00578396 | Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04205071 | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer | withdrawn | Phase 1 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 19, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT02336984 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT03782363 | Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.(CAST) | withdrawn | Phase 1 | 0 | Italian Sarcoma GroupNETWORK | 1 | Dec 22, 2020 | clinicaltrials |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT04195373 | A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract | withdrawn | Phase 1 | 0 | Themis Bioscience GmbHINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | withdrawn | Phase 1 | 0 | Raphael Bueno, MDOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Centre, SingaporeOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Nov 3, 2020 | clinicaltrials |
| NCT04315155 | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation(BENEFIT) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 0 | Oct 28, 2020 | clinicaltrials |
| NCT03846583 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT03177252 | Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients(Scalp block) | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT03443622 | Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors | withdrawn | Phase 1 | 0 | SupremeCure Pharma Inc.INDUSTRY | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03110588 | Phase I Trial of PACE for Metastatic Prostate Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | withdrawn | Phase 1 | 0 | Sherif FaragOTHER | 0 | Oct 12, 2020 | clinicaltrials |
| NCT02487459 | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | withdrawn | Phase 1 | 0 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | withdrawn | Phase 1 | 0 | Bellicum PharmaceuticalsINDUSTRY | 0 | Oct 5, 2020 | clinicaltrials |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) | withdrawn | Phase 1 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 28, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT01916187 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma | withdrawn | Phase 1 | 0 | NCIC Clinical Trials GroupNETWORK | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01079793 | Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2021source: clinicaltrials